Puromycin dihydrochloride CAS: 58-58-2
MF: C22H29N7O5•2HCl
MW: 544.43

Puromycin dihydrochloride (CAS 58-58-2)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 104ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Puromycin dihydrochloride is rated 4.93 out of 5 by 14.
loading
5
13
4
1
3
0
2
0
1
0
Noms alternatifs: Puromycin dihydrochloride is also known as Stylomycin hydrochloride
Application: Puromycin dihydrochloride is an antibiotic used for selection and maintenance of cell lines expressing a transfected pac gene
Numéro CAS: 58-58-2
Pureté: ≥98%
Masse Moléculaire: 544.43
Formule Moléculaire: C22H29N7O52HCl
Pour la Recherche Uniquement. Non conforme pour le Diagnostic ou pour une Utilisation Thérapeutique.
* Consulter le Certificat d'Analyses pour les données spécifiques à un lot (incluant la teneur en eau).
DISCOUNT: Bulk orders of Chemicals totaling $1,000 or more receive a 5% discount.
Postez un avis sur ce produit et recevez 15 CruzCredits
loading

Puromycin dihydrochloride, also known as Stylomycin hydrochloride, is an aminonuclease antibiotic used for selection and maintenance of cell lines expressing a transfected pac gene, whose product, puromycin-N-acetyl-transferase, inactivates puromycin via acetylation.
Puromycin dihydrochloride has been cell culture tested and is recommended for selection of stably transfected cells following transfection with Santa Cruz Biotechnology shRNA or Lentiviral particles. Puromycin dihydrochloride is an antibiotic substance produced by the soil actinomycete Streptomyces alboniger which induces apoptosis in cells by interfering with RNA function, leading to inhibition of protein synthesis. Puromycin dihydrochloride is thought to act as an acyl-tRNA analogue causing premature chain termination. Toxic to both eukaryotic and prokaryotic cells, Puromycin dihydrochloride has also been shown to arrest cells in G2/M phase.


Références

1. Brunetti, M., et al. 1995. Blood. 86: 4199-4205. PMID: 7492778
2. Constam, D.B., et al. 1995. J. Biol. Chem. 270: 26931-26939. PMID: 7592939
3. Sugita, M., et al. 1995. Zool. Sci. 12: 419-425. PMID: 8528014
4. Tabuchi, I. 2003. Biochem. Biophys. Res. Commun. 305: 1-5. PMID: 12732187

Utilisation :
For the selection of stably transfected cells following transfection with Santa Cruz Biotechnology shRNA or Lentiviral particles, proceed with puromycin selection as follows:

NOTE: The working puromycin concentration for selection in mammalian cell lines ranges from 1-10 µg/ml. Prior to using the puromycin antibiotic, titrate the selection agent to determine the optimal concentration for target cell line (see below). Use the lowest concentration that kills 100% of non-transfected cells in 3-5 days from the start of puromycin selection.


•48 hours post-transfection, aspirate the medium and replace with fresh medium containing puromycin at the appropriate concentration.

•Approximately every 2-3 days, aspirate and replace with freshly prepared selective media.

•Monitor the cells daily. Puromycin selection requires a minimum of 48 hours. Optimum effectiveness should be reached within 3-10 days.

•Assay transfected cells.

NOTE: Lot-to-lot variations in potency exist for all selection antibiotics, each new lot of puromycin should be titrated.
Titrating puromycin for selecting transfected cell lines:

•Plate 2 x 105 cells in each well of a 6-well plate containing 3 ml of the appropriate complete medium plus increasing concentrations of puromycin (i.e., 0, 1.0, 2.5, 5.0, 7.5, and 10.0 µg/ml)

•Replace with fresh selective medium after 2 days to remove dead cells.

•Examine the wells for viable cells every two days.

•Monitor the cells daily and observe the percentage of surviving cells. Optimum effectiveness should be reached in 1-4 days.

•The minimum antibiotic concentration to use is the lowest concentration that kills 100% of the cells in 3-5 days from the start of puromycin selection.
Apparence :
Powder
État Physique :
Solid
Dérivé de :
Streptomyces alboniger
Solubilité :
Soluble in water (50 mg/ml), ethanol (~1 mg/ml), DMSO (~13 mg/ml), DMF (~14 mg/ml), and PBS, pH 7.2 (~10 mg/ml).
STOCKAGE :
Desiccate at -20° C
Point de fusion :
178-180° C
Pour la Recherche Uniquement. Non conforme pour le Diagnostic ou pour une Utilisation Thérapeutique.
WGK Allemagne :
3
RTECS :
AU7355000
PubChem CID :
Index Merck :
14: 7943
Numéro MDL :
MFCD00012691
Numéro CE :
200-387-8
Registre Beilstein :
3853613
SMILES :
CN(C)C1=NC=NC2=C1N=CN2[[email protected]]3[[email protected]@H]([[email protected]@H]([[email protected]](O3)CO)NC(=O)[[email protected]@H](CC4=CC=C(C=C4)OC)N)O.Cl.Cl

Télécharger la Fiche de Sécurité/ SDS (MSDS)

CERTIFICAT D'ANALYSE

Pour une bonne lecture, Adobe Acrobat Reader est requis,
imprimer et commenter les documents PDF

Puromycin dihydrochloride (CAS 58-58-2)  Références bibliographiques

Consultez les publications faisant référence à l' utilisation de Puromycin dihydrochloride (CAS 58-58-2). Cliquez sur le lien pour afficher lentrée PubMed .

Citations 1 à 10 sur un total de 300

PMID: # 34157361  Li, D.|Lai, W.|Wang, Q.|Xiang, Z.|Nan, X.|Yang, X.|Fang, Q.| et al. 2021. Biochimie. 189: 65-75.

PMID: # 34614034  Khatiwada, S.|Delhon, G.|Chaulagain, S.|Rock, DL.| et al. 2021. PLoS Pathog. 17: e1009971.

PMID: # 34686329  Toullec, D.|Elías-Villalobos, A.|Faux, C.|Noly, A.|Lledo, G.|Séveno, M.|Helmlinger, D.| et al. 2021. Cell Rep. 37: 109867.

PMID: # 33436530  Li, F.|Zhang, J.|Chen, A.|Liao, R.|Duan, Y.|Xu, Y.|Tao, L.| et al. 2021. Aging (Albany NY). 13: 262-278.

PMID: # 34576070  Wang, L.|Su, Y.|Choi, WS.| et al. 2021. Int J Mol Sci. 22:

PMID: # 34384544  Caielli, S.|Cardenas, J.|de Jesus, AA.|Baisch, J.|Walters, L.|Blanck, JP.|Balasubramanian, P.|Stagnar, C.|Ohouo, M.|Hong, S.|Nassi, L.|Stewart, K.|Fuller, J.|Gu, J.|Banchereau, JF.|Wright, T.|Goldbach-Mansky, R.|Pascual, V.| et al. 2021. Cell.

PMID: # 33899329  Molnár, T.|Pallagi, P.|Tél, B.|Király, R.|Csoma, E.|Jenei, V.|Varga, Z.|Gogolák, P.|Hueber, AO.|Máté, Z.|Erdélyi, F.|Szabó, G.|Pettkó-Szandtner, A.|Bácsi, A.|Virág, L.|Maléth, J.|Koncz, G.| et al. 2021. FEBS J.

PMID: # 34439112  Bamodu, OA.|Wang, YH.|Ho, CH.|Hu, SW.|Lin, CD.|Tzou, KY.|Wu, WL.|Chen, KC.|Wu, CC.| et al. 2021. Cancers (Basel). 13:

PMID: # 33756106  Villa, E.|Sahu, U.|O'Hara, BP.|Ali, ES.|Helmin, KA.|Asara, JM.|Gao, P.|Singer, BD.|Ben-Sahra, I.| et al. 2021. Mol Cell.

PMID: # 34514093  Wei, QT.|Liu, BY.|Ji, HY.|Lan, YF.|Tang, WH.|Zhou, J.|Zhong, XY.|Lian, CL.|Huang, QZ.|Wang, CY.|Xu, YM.|Guo, HB.| et al. 2021. Mol Ther Oncolytics. 22: 114-128.

Citations 1 à 10 sur un total de 300
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 93ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 7ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;